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health conditions, and the demographic variables. We also report
QOL weights for the self-reported health state and priority
health conditions, by the demographic variables. Finally, ordi-
nary least squares and CLAD regression equations were used to
estimate adjusted QOL weights for these variables. CONCLU-
SION: By providing nationally representative QOL weights for
self-reported health status and priority health conditions, by
demographic variable, we have facilitated the use of large
national surveys for conducting cost-utility analysis and
increased their value to researchers and policy makers.
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OBJECTIVES: To identify treatment satisfaction thresholds for
interpreting treatment–related changes in vasomotor symptoms,
and determine the doses of desvenlafaxine succinate (DVS) that
effectively provide relief of vasomotor symptoms considered
important by menopausal women. METHODS: Efﬁcacy and
treatment satisfaction were assessed in 620 postmenopausal
women with ≥7 moderate-to-severe vasomotor symptoms/day
participating in a double-blind, placebo-controlled trial ran-
domized to placebo or DVS 50, 100, 150, or 200 mg. Number
and severity of hot ﬂushes and number of nighttime awakenings
were recorded in daily diaries for 12 weeks of treatment.
Responses to the Menopausal Symptoms Treatment Satisfaction
Questionnaire at week 12 were compared with efﬁcacy results.
The treatment satisfaction threshold was anchored by the dif-
ference in the average symptom change among women report-
ing “neutral” satisfaction compared with women reporting
“satisﬁed,” without deference to treatment group. RESULTS:
Greater percentages of participants in the DVS groups reported
being “satisﬁed” or “extremely satisﬁed” with daytime and
nighttime control of hot ﬂushes compared with placebo
(57–75% versus 52%; P = 0.009 and 63–80% versus 54%; P =
0.003). These efﬁcacy results were greatest in the 100 mg DVS
group. The treatment satisfaction threshold was 1.64 for daytime
hot ﬂushes, 0.20 for the hot ﬂushes severity score, and 0.42 for
nighttime awakenings. Statistically signiﬁcant efﬁcacy outcomes
with DVS 100 mg compared with placebo exceeded all treatment
satisfaction thresholds. CONCLUSION: Among menopausal
women in this study, the treatment satisfaction thresholds in
vasomotor symptoms reduction over placebo were 1.64 hot
ﬂushes per day and about one nighttime awakening every other
night. Exceeding these vasomotor symptoms change thresholds
indicated that the 100 mg dose of DVS had achieved important
and meaningful improvements from the participants’ perspec-
tive. DVS is an effective option for treatment of vasomotor symp-
toms associated with menopause.
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OBJECTIVES: To determine the cost-effectiveness of treatments
for patients with acute (RSA) and chronic rhinosinusitis (RSC)
that are available at the Mexican Institute of Social Security
(IMSS). METHODS: Cost-effectiveness analysis of RSA and
RSC treatment from an institutional perspective. Effectiveness
outcome was deﬁned as the percentage of cure and this infor-
mation was taken from the literature. Use of resources was
obtained from an expert panel and unit costs were taken from
Administrative and Financial departments from IMSS. Estimated
costs are expressed in US dollars (USD). A decision tree with a
Bayesian approach included the following therapeutic alterna-
tives: ciproﬂoxacin, gatiﬂoxacin, trimetoprim/sulfametoxazol
(TMP/SMX), amoxicilin/clavulanic acid (AAC) and clindamicin.
The decision tree was designed by IMSS experts according to
clinical guidelines. Univariate and bivariate sensitivity analyses
were carried out. RESULTS: Treatment for RSA with AAC
showed a mean cost per cured patient of $79.8 USD. The remain-
ing antibiotics had a higher cost per unit of success, and there-
fore the results showed that AAC was the best alternative
considering this criterion. The rapy that showed a larger per-
centage of cured patients in RSC was clindamicin (cost per unit
of success 666.3 USD); however, the therapeutic alternative with
the lowest cost per successful unit was the one based on
ciproﬂoxacin, which dominates gatiﬂoxacin and AAC. CON-
CLUSION: Ciproﬂoxacin is a cost-effective alternative for both,
RSA and RSC; however, AAC is also a good alternative in RSA
when resources are constrained. Sensitivity analysis showed the
strength of the base study results.
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OBJECTIVES: Assess differences in treatment response between
weight-based peginterferon alfa-2b (PEG2b) or standard dosed
peginterferon alfa-2a (PEG2a) plus weight-based ribavirin
(RBV); identify patient variables that may predict treatment
response; and evaluate differences in cost-effectiveness.
METHODS: We compared two retrospective assessments of the
treatment of hepatitis C virus (HCV) infected patients at two 
different VAs. The primary outcome was sustained virologic
response (SVR), deﬁned as an undetectable viral load 6 months
post-therapy completion. All patients were treatment naïve and
had received at least 2 doses of PEG 2a or 2b plus RBV prior to
January 2005 (n = 151). RESULTS: SVR among genotype 1 and
genotype 2/3 patients was 21% and 71% for PEG2a versus 20%
and 70% for PEG2b, respectively. Premature treatment discon-
tinuation due to an adverse event occurred among 36% of
PEG2a and 40% of PEG2b patients. The overall relapse rate was
29% for each regimen. There was a statistically signiﬁcant dif-
ference in baseline age and weight between the two groups.
Overall mean age +SD was 52 + 6 years for PEG2a and 49 + 7
years for PEG2b (P = 0.001); overall mean body weight was 94
+ 18 kg for PEG2a and 86 + 13 for PEG2b (P = 0.008). Cost per
successful outcome (deﬁned as SVR) for genotype 1 and geno-
type 2/3 was $36,567 and $4958 for PEG2a versus $38,670 and
$5060 for PEG2b, respectively. CONCLUSION: There were no
statistically signiﬁcant differences between peginterferon alfa-2a
and peginterferon alfa-2b in terms of treatment response or cost-
effectiveness; however dissimilarities in the variables associated
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with baseline population characteristics may potentially con-
found these ﬁndings.
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OBJECTIVES: To examine treatment failure rates, disease-
related medical complications and health care costs among CAP
outpatients treated with levoﬂoxacin (LEVO) or amoxicillin/
clavulanate (AC). METHODS: Using adjudicated, commercial
health insurance claims data (PharMetrics, Inc.), patients with
an outpatient CAP diagnosis between July 2003 and December
2004, aged 18–64, with 6-months enrollment pre– and
post–diagnosis, receiving LEVO or AC monotherapy within 3
days of diagnosis, were identiﬁed. Patients with recent hospital-
ization (10 days), prior antibiotic therapy (30 days), or immuno-
compromised state were excluded. Treatment failure was deﬁned
as receipt of a renewal or alternative antibiotic claim, or hospi-
talization 28 days post–prescription claim. Complications and
infection related costs were tracked for 6-months post–
diagnosis. Demographic, clinical, pre–index utilization, and
study endpoints were evaluated via descriptive, univariate
(Wilcoxon and Chi-Square tests for continuous and dichotomous
variables, respectively) and multivariate techniques (logistic
regression for treatment failure and complications, General
Linear Model for costs). RESULTS: Of 4030 LEVO and 951 AC
patients analyzed, the cohorts had similar demographic and clin-
ical proﬁles (pre–diagnosis utilization and cost, comorbidity
burden, Charlson score), except age (LEVO vs AC: 45.8 vs. 42.7
y, p < 0.001), gender distribution (females 49.5% vs. 53.4%, p
< 0.001), and asthma prevalence (4.9% vs 6.8%, p = 0.017). The
AC group had a higher percentage (22.0% vs. 18.5%, p = 0.015)
and likelihood (OR = 1.27, 95% CI 1.07–1.52, p = 0.007) of
treatment failure than the LEVO group. The rates of infec-
tion–related complications were 8.6% for LEVO and 8.2% for
AC; (OR 1.12, 95% CI 0.80–1.56, p = 0.52). No difference was
observed in infection–related costs (mean ± SD: LEVO $1067 ±
3562 vs. AC $1159 ± 5874). CONCLUSION: LEVO and AC
groups were comparable. The LEVO group experienced signiﬁ-
cantly lower treatment failure, but no signiﬁcant differences in
complications or costs, compared to the AC group, in outpatient
CAP.
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OBJECTIVES: To examine treatment failure rates among com-
munity acquired pneumonia (CAP) patients treated with lev-
oﬂoxacin vs. macrolides (azithromycin, clarithromycin or
erythromycin) in an outpatient setting. METHODS: A post-hoc,
retrospective database analysis using eligibility (6-months pre
and post), medical and pharmacy claims from a large US com-
mercial health plan. Adults (≥18) with an outpatient primary
diagnosis of CAP between January 1, 2004 and March 31, 2005,
and treated within 3 days of diagnosis with oral levoﬂoxacin or
macrolides were included. Patients with a recent hospitalization
(10 days), prior antibiotic therapy (30 days), or immunocom-
promised state were excluded. Treatment failure was deﬁned as
receipt of receipt of renewal or alternative antibiotic claim, or
hospitalization for CAP within 30 days of initial therapy. Mul-
tivariate logistic regression compared treatment failure rates
between the two groups. Multivariate regression included all rel-
evant variables describing patient characteristics including age,
gender, region, Charlson comorbidity score, pre-existing respi-
ratory, cardiovascular disease and diabetes. An identical sub-
group analysis of patients ≥50 years old was conducted.
RESULTS: Of 7526 CAP patients included, 2968 (39.4%) were
treated with levoﬂoxacin and 4558 (60.6%) with a macrolide.
Levaquin patients were older (mean 48.7 vs. 43.7) and had a
more severe Charlson comorbidity status (mean 0.40 vs. 0.25).
Unadjusted treatment failure rates were 21.1% and 22.7% in
levoﬂoxacin and macrolide cohorts, respectively. After adjust-
ment, compared to macrolides, levoﬂoxacin patients were less
likely to fail treatment (OR = 0.84, 95% CI: 0.73, 0.94, P =
0.002). Of 2967 subjects ≥50 years old, 21.8% of levoﬂoxacin
and 25.4% of macrolide patients failed treatment, respectively;
likelihood of treatment failure was signiﬁcantly lower for lev-
oﬂoxacin patients (OR = 0.79, 95% CI: 0.66, 0.94, P = 0.007).
CONCLUSION: Compared with macrolides, Levoﬂoxacin was
associated with lower treatment failure rates in CAP patients
treated in an outpatient setting. This difference was greater in
patients ≥50 years old.
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OBJECTIVES: Vancomycin is often considered ﬁrst-line for com-
plicated gram+ infections; however, a rise in resistant infections
in both hospital and community settings may impact efﬁcacy and
total cost of treatment. Our objective was to systematically eval-
uate the clinical efﬁcacy and resource use/economic characteris-
tics of vancomycin in recent randomized clinical trials (RCT) or
economic studies for treatment of complicated gram+ infections,
such as skin and soft tissue infections (SSTI), including methi-
cillin-resistant staphylococcus aureus (MRSA). METHODS: A
literature search was conducted in PubMed, EMBASE, IPA, and
infectious disease abstract databases to identify clinical or eco-
nomic studies of vancomycin published from 2000–2006. Clin-
ical outcomes data were synthesized by study design, infection
type, MRSA status, intent to treat (ITT) efﬁcacy, microbiologic
cure, MRSA efﬁcacy, and adverse events (AEs). Efﬁcacy data
were pooled when possible. Economic data abstracted included
hospital length of stay (LOS), length of treatment (LOT), and
cost of treatment (COT) adjusted to 2006 US$. RESULTS:
Twelve studies (including 5 RCTs with 4 in SSTI) were identiﬁed
reporting speciﬁc clinical efﬁcacy outcomes and/or economic
data. The ITT average efﬁcacy (range) for vancomycin 1 gm IV
q12hr for SSTIs was 85% (76.9–88.5%) and microbiologic cure
was 89% (77–97.6%). For MRSA SSTIs, efﬁcacy was lower at
68% (50–81%). Incidence of drug-related AEs was 3.6–20.6%,
and drug-related discontinuations 4.5–5.8%. Hospital LOS
ranged from 8–15 days, and LOT 9–11 days. Resistance
